Prostamax (KEDP) — Khavinson Peptide Research Archive

The extract (Prostatilen) has Russian clinical literature including a Khavinson-group chronic prostatitis trial; the synthetic sold globally has zero human trials.

Extract counterpart: Prostatilen / Vitaprost — prostate extract (registered RU drug). ZERO human trials of the synthetic tetrapeptide exist.

Extract vs synthetic gap: the human outcome data (including the 266-patient mortality cohort) was collected on extracts; vendors sell synthetic fragments. No head-to-head trial exists — evidence does not transfer between them. Details →

Khavinson studies (1 matched, years n.d.)

Keyword-filtered from the 472-publication database (khavinson.info). EXTRACT/SYNTHETIC tags are title-text heuristics — verification is on the reader. Full tag legend: evidence-tiers.html

[232] Gorpinchenko I.I., Khavinson V.Kh., Boiko N.I., Drannik G.N., Tonkonogaia L.A. Treatment of chronic prostatitis, complicated by pathospermia with the polypeptide preparation of the prostatic gland. // 4th International Congress of Reproductive Immunology. - Abstr.: J. of Reproductive Immunology. - 1989. - Suppl. - P. 124. (n.d.)ext

Independent (non-Khavinson) studies

None catalogued. To date there are zero independent Western human trials of any Khavinson compound, in any year. Independent in-vitro data exists for Epitalon only (two 2025 studies). If a study belongs here, add it to non-khavinson-research.json and rebuild.

Reddit meta-scrape

Dedicated meta-review completed Aug 28 2026 at vault/wiki/concepts/prostamax-kedp-reddit-meta-review.md. Summarized here.

Positive reports

Better urinary flow (symptomatic men only)
Reduced inflammation/pain in chronic prostatitis reports
Painful ejaculation resolved in some reports

Neutral / no-effect

~30% of reporters: 'did nothing'

Negative reports

One paradoxical prostate-pain report
Nobody documented actual size reduction (ultrasound)

MEASURED vs VIBE: 0 measured out of ~15 reports. No user posted IPSS score, PSA change, or ultrasound data. All subjective symptom reports.

Common protocol: Consensus: 1-2mg/day SQ x 20-30 days, then 3-6 months off. One vial = one cycle.

Key takeaway: Positive reports all from SYMPTOMATIC men. Zero anecdotes for prophylactic/asymptomatic use. Clean safety profile. Zero PSA-change reports. Evidence for the extract (Prostatilen) does NOT transfer to the synthetic tetrapeptide.

Measurement protocol — concrete testable endpoints

IPSS symptom score, PSA, prostate volume (ultrasound), urinary flow rate (Qmax). NOT subjective "feels better."

All endpoints on one page: measurement-protocols.html · Evidence-tier legend: evidence-tiers.html